Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 33

1.

On the contribution of Angola to the initial spread of HIV-1.

Pineda-Peña AC, Varanda J, Sousa JD, Theys K, Bártolo I, Leitner T, Taveira N, Vandamme AM, Abecasis AB.

Infect Genet Evol. 2016 Aug 10. pii: S1567-1348(16)30346-X. doi: 10.1016/j.meegid.2016.08.009. [Epub ahead of print]

PMID:
27521160
2.

Sub-Epidemics Explain Localized High Prevalence of Reduced Susceptibility to Rilpivirine in Treatment-Naive HIV-1-Infected Patients: Subtype and Geographic Compartmentalization of Baseline Resistance Mutations.

Theys K, Van Laethem K, Gomes P, Baele G, Pineda-Peña AC, Vandamme AM, Camacho RJ, Abecasis AB.

AIDS Res Hum Retroviruses. 2016 May;32(5):427-33. doi: 10.1089/AID.2015.0095. Epub 2016 Jan 29.

3.

Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals.

Winand R, Theys K, Eusébio M, Aerts J, Camacho RJ, Gomes P, Suchard MA, Vandamme AM, Abecasis AB; Portuguese HIV-1 Resistance Study Group.

AIDS. 2015 Sep 24;29(15):2045-52. doi: 10.1097/QAD.0000000000000811. Erratum in: AIDS. 2016 Feb 20;30(4):679.

4.

Lack of evidence for the selection of E138 mutations by first-generation non-nucleoside reverse transcriptase inhibitors in patients infected with HIV-1 non-B subtypes.

Abecasis AB, van Laethem K, Theys K.

AIDS. 2015 May 15;29(8):987-8. doi: 10.1097/QAD.0000000000000627. No abstract available.

PMID:
25909833
5.

Bridging epidemiology with population genetics in a low incidence MSM-driven HIV-1 subtype B epidemic in Central Europe.

Lunar MM, Vandamme AM, Tomažič J, Karner P, Vovko TD, Pečavar B, Volčanšek G, Poljak M, Abecasis AB.

BMC Infect Dis. 2015 Feb 15;15:65. doi: 10.1186/s12879-015-0802-6.

6.

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe.

Frentz D, Van de Vijver DA, Abecasis AB, Albert J, Hamouda O, Jørgensen LB, Kücherer C, Struck D, Schmit JC, Vercauteren J, Åsjö B, Balotta C, Beshkov D, Camacho RJ, Clotet B, Coughlan S, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Liitsola K, Linka M, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Stanekova D, Stanojevic M, Van Wijngaerden E, Wensing AM, Boucher CA; SPREAD Programme.

BMC Infect Dis. 2014 Jul 21;14:407. doi: 10.1186/1471-2334-14-407.

7.

Novel HIV-1 recombinants spreading across multiple risk groups in the United Kingdom: the identification and phylogeography of Circulating Recombinant Form (CRF) 50_A1D.

Foster GM, Ambrose JC, Hué S, Delpech VC, Fearnhill E, Abecasis AB, Leigh Brown AJ, Geretti AM; UK HIV Drug Resistance Database.

PLoS One. 2014 Jan 15;9(1):e83337. doi: 10.1371/journal.pone.0083337. eCollection 2014.

8.

Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort.

Bartha I, Assel M, Sloot PM, Zazzi M, Torti C, Schülter E, De Luca A, Sönnerborg A, Abecasis AB, Van Laethem K, Rosi A, Svärd J, Paredes R, van de Vijver DA, Vandamme AM, Müller V.

BMC Infect Dis. 2013 Nov 12;13:537. doi: 10.1186/1471-2334-13-537.

9.

inTB - a data integration platform for molecular and clinical epidemiological analysis of tuberculosis.

Soares P, Alves RJ, Abecasis AB, Penha-Gonçalves C, Gomes MG, Pereira-Leal JB.

BMC Bioinformatics. 2013 Aug 30;14:264. doi: 10.1186/1471-2105-14-264.

10.

Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools.

Pineda-Peña AC, Faria NR, Imbrechts S, Libin P, Abecasis AB, Deforche K, Gómez-López A, Camacho RJ, de Oliveira T, Vandamme AM.

Infect Genet Evol. 2013 Oct;19:337-48. doi: 10.1016/j.meegid.2013.04.032. Epub 2013 May 7.

11.

Limited cross-border infections in patients newly diagnosed with HIV in Europe.

Frentz D, Wensing AM, Albert J, Paraskevis D, Abecasis AB, Hamouda O, Jørgensen LB, Kücherer C, Struck D, Schmit JC, Åsjö B, Balotta C, Beshkov D, Camacho RJ, Clotet B, Coughlan S, De Wit S, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Liitsola K, Linka M, Nielsen C, Otelea D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Stanekova D, Stanojevic M, Vandamme AM, Boucher CA, Van de Vijver DA; SPREAD Programme.

Retrovirology. 2013 Apr 3;10:36. doi: 10.1186/1742-4690-10-36.

12.

HIV-1 drug resistance: where do polymorphisms fit in?

Theys K, Abecasis AB, Vandamme AM.

Future Microbiol. 2013 Mar;8(3):303-6. doi: 10.2217/fmb.13.10. No abstract available.

PMID:
23464368
13.

A genomic signature and the identification of new sporulation genes.

Abecasis AB, Serrano M, Alves R, Quintais L, Pereira-Leal JB, Henriques AO.

J Bacteriol. 2013 May;195(9):2101-15. doi: 10.1128/JB.02110-12. Epub 2013 Feb 8.

14.

HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics.

Abecasis AB, Wensing AM, Paraskevis D, Vercauteren J, Theys K, Van de Vijver DA, Albert J, Asjö B, Balotta C, Beshkov D, Camacho RJ, Clotet B, De Gascun C, Griskevicius A, Grossman Z, Hamouda O, Horban A, Kolupajeva T, Korn K, Kostrikis LG, Kücherer C, Liitsola K, Linka M, Nielsen C, Otelea D, Paredes R, Poljak M, Puchhammer-Stöckl E, Schmit JC, Sönnerborg A, Stanekova D, Stanojevic M, Struck D, Boucher CA, Vandamme AM.

Retrovirology. 2013 Jan 14;10:7. doi: 10.1186/1742-4690-10-7.

15.

HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.

Theys K, Vercauteren J, Snoeck J, Zazzi M, Camacho RJ, Torti C, Schülter E, Clotet B, Sönnerborg A, De Luca A, Grossman Z, Struck D, Vandamme AM, Abecasis AB.

Antimicrob Agents Chemother. 2013 Feb;57(2):1053-6. doi: 10.1128/AAC.01668-12. Epub 2012 Nov 26.

16.

Phylogeography of dengue virus serotype 4, Brazil, 2010-2011.

Nunes MR, Faria NR, Vasconcelos HB, Medeiros DB, Silva de Lima CP, Carvalho VL, Pinto da Silva EV, Cardoso JF, Sousa EC Jr, Nunes KN, Rodrigues SG, Abecasis AB, Suchard MA, Lemey P, Vasconcelos PF.

Emerg Infect Dis. 2012 Nov;18(11):1858-64. doi: 10.3201/eid1811.120217.

17.

Decreasing population selection rates of resistance mutation K65R over time in HIV-1 patients receiving combination therapy including tenofovir.

Theys K, Snoeck J, Vercauteren J, Abecasis AB, Vandamme AM, Camacho RJ; Portuguese HIV-1 Resistance Study Group.

J Antimicrob Chemother. 2013 Feb;68(2):419-23. doi: 10.1093/jac/dks380. Epub 2012 Sep 30.

18.

Short communication: prevalence of HIV type 1 transmitted drug resistance in Slovenia: 2005-2010.

Lunar MM, Židovec Lepej S, Abecasis AB, Tomažič J, Vidmar L, Karner P, Vovko TD, Pečavar B, Maver PJ, Seme K, Poljak M.

AIDS Res Hum Retroviruses. 2013 Feb;29(2):343-9. doi: 10.1089/AID.2012.0152. Epub 2012 Aug 29.

19.

Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility.

Santos AF, Tebit DM, Lalonde MS, Abecasis AB, Ratcliff A, Camacho RJ, Diaz RS, Herchenröder O, Soares MA, Arts EJ.

Antimicrob Agents Chemother. 2012 May;56(5):2719-25. doi: 10.1128/AAC.06079-11. Epub 2012 Feb 13.

20.

Origin and epidemiological history of HIV-1 CRF14_BG.

Bártolo I, Abecasis AB, Borrego P, Barroso H, McCutchan F, Gomes P, Camacho R, Taveira N.

PLoS One. 2011;6(9):e24130. doi: 10.1371/journal.pone.0024130. Epub 2011 Sep 28.

Items per page

Supplemental Content

Loading ...
Write to the Help Desk